Stomatology Department, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
International Research Center, A.C. Camargo Cancer Center, São Paulo, SP, Brazil.
Oral Dis. 2018 Mar;24(1-2):207-209. doi: 10.1111/odi.12771.
A total of 115 patients who used everolimus were evaluated. The mean age was 57 (±13.3) years old, and 87 patients were women (75.6%). mTOR inhibitor-associated stomatitis (mIAS) was observed in 36 patients (31.3%). The lesions ranged from 0.5 cm to 1.5 cm, and the tongue was the main site affected. In addition, 21 patients (58.3%) required a dose reduction of everolimus due to mIAS. Patients who had breast cancer presented 2.29-fold higher risk for developing mIAS when compared to patients with kidney or neuroendocrine tumors. This study emphasizes the high prevalence of mIAS in patients using everolimus, in particular, in patients with breast cancer.
共评估了 115 例使用依维莫司的患者。患者平均年龄为 57（±13.3）岁，87 例为女性（75.6%）。36 例（31.3%）患者出现依维莫司相关口腔炎（mIAS）。病变范围从 0.5cm 到 1.5cm，主要累及部位为舌。此外，21 例（58.3%）患者因 mIAS 而减少了依维莫司的剂量。与患有肾或神经内分泌肿瘤的患者相比，患有乳腺癌的患者发生 mIAS 的风险高 2.29 倍。本研究强调了使用依维莫司的患者中 mIAS 的高发生率，特别是患有乳腺癌的患者。
